



COPY

PATENT
ATTORNEY DOCKET NO. 045636-5037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Guy SERRE et al.)	
)	
Application No.: Unassigned)	Group Art Unit: Unassigned
)	
Date of National Stage Entry: June 30, 2000)	
)	Examiner: Unassigned
Based on: PCT/FR98/02899)	
)	
Filed: December 29, 1998)	
)	
For: PEPTIDE EPITOPES RECOGNIZED BY)	
ANTI-FILAGGRIN AUTO-ANTIBODIES)	
IN SERUM FROM RHEUMATOID)	
ARTHRITIS PATIENTS)	

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed within three months of the date of the National Stage entry of the above-referenced application. Accordingly, Applicants do not believe that a fee is due for filing this paper.

A copy of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

An International Search Report, citing the documents and setting forth the relevance thereof are also enclosed for the Examiner's consideration. In addition to this citation the relevance of French language document WO 98/08946 is noted on page 4, lines 21-32, of the specification, which cites the French priority document of this publication.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If it should be determined that the listed documents do constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR
EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Elizabeth C. Weimar
Reg. No. 44.478

Dated: June 30, 2000

MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869
(202) 467-7000



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. 045636-5037		Application No.: Unassigned	
				Applicants: Guy SERRE et al. PAGE 1 of 1			
				Filing Date: June 30, 2000		Group Art Unit: Unassigned	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	<u>Translation</u> YES NO
		WO 98 08946	03/5/1998	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		E Girbal-Neuhauser et al., "The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (Pro)filaggrin by deimination of arginine residues", <u>Journal of Immunology</u> , vol. 162, no. 1, 1 January 1999, pages 585-594					
		G. A. Schellekens et al., "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific antibodies", <u>J. Clin. Invest.</u> , vol. 101, no. 1, 1 January 1998, abstract					
		G. A. Schellekens et al., "The Modified Arginine Residue Citrullines Is The Major Constituent Of Epitopes Recognized by Autoantibodies In Sera From Rheumatoid Arthritis Patients", <u>Arthritis and Rheumatism</u> , vol. 40, no. 9, Suppl. 08, November 8, 1997, abstract.					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED RECEIVED

JUN 24 2002

JUN 24 2002

TECH CENTER

TECH CENTER 1600/2900